GO
| HSI1 | 25,238.22 | -72.99 | 144.32B |
| HSCEI1 | 8,395.01 | -55.09 | 40.78B |
| Back Zoom + Zoom - Block Traded | |
|
AKESO (09926.HK) Ivonescimab First-line Treatment for PD-L1-positive NSCLC Phase III Study Meets Key Secondary OS Endpoint
2026-09-03 09:47:31 AKESO (09926.HK) announced that the interim analysis of overall survival (OS), a pre-specified assessment conducted by the Independent Data Monitoring Committee, showed that the Phase III HARMONi-2 clinical study of its self-developed, globally first-in-class bispecific antibody "Ivonescimab" (PD-1/VEGF) versus pembrolizumab (Keytruda) for first-line treatment of PD-L1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) met the key secondary OS endpoint, delivering statistically significant and clinically meaningful positive results. The study enrolled a total of 398 subjects. The primary endpoint was progression-free survival (PFS), while the key secondary endpoint was OS. The company said the latest OS results further demonstrated the breakthrough clinical value of Ivonescimab as a next-generation cornerstone immuno-oncology therapy.(gc/u)~ AASTOCKS Financial News Website: www.aastocks.com This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. | |